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Heterozygous activating mutations in the KCNJ11 gene encoding the pore-forming Kir6.2 subunit of the pancreatic beta
cell KATP channel are the most common cause of permanent neonatal diabetes (PNDM). Patients with PNDM due to a
heterozygous activating mutation in the ABCC8 gene encoding the SUR1 regulatory subunit of the KATP channel have
recently been reported. We studied a cohort of 59 patients with permanent diabetes who received a diagnosis before 6
mo of age and who did not have a KCNJ11 mutation. ABCC8 gene mutations were identiﬁed in 16 of 59 patients and
included 8 patients with heterozygous de novo mutations. A recessive mode of inheritance was observed in eight patients
with homozygous, mosaic, or compound heterozygous mutations. Functional studies of selected mutations showed a
reduced response to ATP consistent with an activating mutation that results in reduced insulin secretion. A novel
mutational mechanism was observed in which a heterozygous activatingmutation resulted in PNDMonlywhen a second,
loss-of-function mutation was also present.
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The KCNJ11 (MIM 600937) and ABCC8 (MIM 600509;
GenBank accession number NM_000352.2 incorporating
the alternate exon 17 [GenBank L78208 and L78224])
genes encode the Kir6.2 and SUR1 subunits of the hetero-
octomeric ATP-sensitive potassium (KATP) channel in the
pancreatic beta cell. KATP channels link cellularmetabolism
to electrical activity of the plasma membrane and play a
key role in regulating insulin secretion. Mutations in the
genes encoding Kir6.2 and SUR1 were ﬁrst reported to
cause a recessive form of congenital hyperinsulinism
(MIM 601820 and 256450) in patients with loss-of-func-
tion mutations that abrogate channel function.1,2 Hetero-
zygous gain-of-function mutations in the KCNJ11 gene
encoding Kir6.2 impair the ability of ATP to close the
channel and are the most common cause of permanent
neonatal diabetes (PNDM [MIM 606176]).3,4 Most of these
patients achieve improved glycemic control after transfer
from insulin injections to sulphonylurea tablets.5 PNDM
resulting from heterozygous activating SUR1 mutations
has been reported in six patients,6–10 and seven index cases
with transient neonatal diabetes have been described.7 No
homozygous or compound heterozygous KATP channel
mutations have been reported in neonatal diabetes.
We studied 84 patients who received a diagnosis of di-
abetes in the ﬁrst 6 mo of life who were treated with in-
sulin from the time of diagnosis. Many of these patients
were recruited from among the members of the Interna-
tional Society of Paediatric and Adolescent Diabetes (IS-
PAD). Heterozygous KCNJ11 mutations were identiﬁed in
25 patients by sequencing using methods described else-
where.11 Mutations in the ABCC8 gene were sought in the
remaining 59 patients by sequence analysis of the 39 ex-
ons and conserved splice sites, with use of the primers
listed in table 1.
ABCC8 mutations were identiﬁed in 16 probands (ﬁg.
1 and table 2) and included 17 novel mutations, which
were not found in 250 control chromosomes. Of these,
15 were novel missense mutations affecting residues that
show evolutionary conservation from human to mouse.
Apparent spontaneous mutations were conﬁrmed by test-
ing parental and probandDNA samples with use of a panel
of six microsatellite markers on chromosome 11p15.11
Heterozygous de novo mutations V86A, V86G, F132L,
F132V, D209E, Q211K, and L225P were present in eight
patients (table 2). In three further families in which chil-
dren with PNDM were born to unaffected parents, novel
ABCC8 mutations were identiﬁed, but the mode of in-
heritance was recessive rather than dominant (ﬁg. 1). Two
homozygous mutations, E382K and A1185E, were present
in probands from pedigrees in which the parents are ﬁrst
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Figure 1. ABCC8 and KCNJ11 gene mutations in patients with PNDM. Pedigrees are shown for recessively inherited ABCC8 mutations.
Solid symbols denote patients with neonatal diabetes and unaffected heterozygous mutation carriers are indicated by a dot. Asterisks
denote those mutations selected for functional analysis.
cousins (ISPAD 117 and 118; see ﬁg. 1). The heterozygous
parents were not diabetic. One patient with PNDM (ISPAD
116) had the N72S mutation and mosaic segmental pa-
ternal isodisomy for chromosome 11pter to 11p14, dem-
onstrated by microsatellite analysis of markers D11S2071,
D11S922, D11S4177, TH, D11S1318, HBB, D11S4149,
D11S1794, D11S904, D11S907, D11S911, D11S4143, and
D11S1332. This region includes the ABCC8 gene, and thus
uniparental disomy has unmasked a recessively actingmu-
tation. The father is heterozygous for the mutation but
does not have diabetes.
Compound heterozygous mutations were identiﬁed in
ﬁve patients (ﬁg. 1). Three probands were compound het-
erozygotes for the missense mutations P45L/G1401R (IS-
PAD 47), E208K/Y263D (ISPAD 119), and T229I/V1523L
(ISPAD 120). The parents were heterozygous for a single
missense mutation, but none were affected with diabetes
(ﬁg. 1). Unexpectedly, two patients were found to be com-
pound heterozygotes for missense and frameshift SUR1
mutations. These heterozygous insertion/deletion muta-
tions in families 78 and 121 (see table 1) result in pre-
mature termination codons that are predicted to be loss-
of-function mutations typically associated with recessive
hyperinsulinism. We showed—in a lymphoblastoid cell
line from the unaffected mother of ISPAD 78, who is het-
erozygous for the c.536del4 mutation—that the mutant
mRNA transcript level was reduced to ∼25% of the normal
transcript (see appendix A for details of methodology and
ﬁg. 2 for results). The mutant mRNA transcript is likely to
be degraded by nonsense-mediated decay, because incu-
bation with the translation inhibitor cycloheximide in-
creased the expression of this transcript twofold (ﬁg. 2).
The second mutation in this family is a novel missense
mutation, P207S (see table 2). Three different mutations
were detected in proband ISPAD 81; the unaffectedmother
is heterozygous for the frameshift mutation c.3127ins10
and the unaffected father carries E1327K and V1523A in
cis (ﬁg. 1). No cell line was available from the heterozygous
frameshift-mutation carrier in this family, but this mu-
tation is also likely to result in loss of function, with re-
duction inmRNA levels and consequently reducedprotein
levels in the cell membrane. We propose that these loss-
of-functionmutations lead to a decrease in functional pro-
tein and that hence the majority of pancreatic KATP chan-
nels will be homomeric for the missense mutation (see
ﬁg. 3).
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Table 1. Primer Sequences for Ampliﬁcation of ABCC8
Exon
Primer (M13 tailed)
Size
(bp)Forwarda Reverseb
1 AGCTGCAAGGGACAGAGG GAGTGAAGGGATGAGCTGG 578
2 GGGATCCTCATGTGTAGGTG AGAAGACACTGAGCTGCTGG 404
3 CCCAAATACGCCCATTAAC GTCTATCCTCCTTCACCAGAC 442
4 AAATGTACACACCCAGGCAC GGGTAAAACAAGCTGATCCC 411
5 AATTACAGGCGAAAGATGGC CTCACCAGCCTCAGTTTCC 501
6 CCTATTTGCAGAGGATGTGAC GATACTGCTATGGGCTTTGC 454
7 GCACAAGCCTTTGCAAGC AAACATCGTTAATGGGCAAC 432
8 AAGTTGGAACGGTGATACAG TGTGAAAGGTACAGGCAAGC 435
9 GATAATTTGGAAACCTGGGC TGAAGTGGCCTACTCAAAGTC 387
10 TCTGGGAAATGGAGTCAATG GAGTCGGATAATCTCAAGGC 432
11 TCCTGGGCATCTCCATG GTGGAGAGCCTGTCTTCTGAGG 260
12 ATGAAGGTGTCTCCAACTAAAAGAT ATCACTCGAGCAAGCCTTG 399
13 GAGCTCTCTATCAGGCTGCGCCCTCT ATGCTGGGAGTAGCAAGGGGAG 254
14 GCTGTGTCGGACTTCTGCCTTT GCTCCCTCTGGGAGTTGGTGc 302
15 GTGTCTTTTGGCTTTCATGGc CAATAAATGCAGCTTTGTCTc 300
16 TCTGGGTAATGGTTGTTCAGc TCCAATAAATGTGTGTGCATc 293
17 ACAGAGGCCATTTGGAAAC TCTGAAAATATGTAGGCTGCAC 298
18 TCTCTATGCAGCATTTGTGG AATGGATGCACAGAAACAGC 366
19 AGACCCAGACCTCTCAAACC GGTGCACCATATGGAGAGG 439
20 GAGGCCTATTAAAGCCATTG TGTTTGACCTTACTGCAGGC 348
21 TGTCTCCTGAATGGCTGAGG GGGAGATTGTTGGATGATGG 194
22 TCCAAAGCCACACAGCTAAC CCAGTGCTGGTCTCTTATGC 404
23 GGTGGCCATTTGTAGTGAGG AGCAGAACCTTTGCATCCAG 286
24 TGAATGTGTGTCTGTCTGCC CAGAGGGAAGCCATTTAATC 370
25 GGTGTGGTGCAGTAGTGTGC AGTGATTTGGAGTTCCAGGG 473
26 CAGGAACTGCTCCCTCAGC CACTGTCTCCTTGAGTCACCC 614
27 TGAATGACTCCAGAGACACTTAc AGACAGGAGAAGCCCCCAGc 282
28 AGTCTGGGCAACAGTGAGAC TAGGGCGGTGGAATAAGATG 466
29 CACGGGGTAAGAAGCTGAG GCTTGAGAGAGAACGTGTCC 349
30 GACATTCCAGAGAGGGATAGC ACACTAGGAGGACCACCAGG 411
31 CCCTTGTGTGTGTCTGGTG AACCTCCACCTGTCTGGG 454
32 GATGGCAGCAAAAGGAATC AGTTCTTTGGGATCAGCG 411
33 AGTCCAAGGAGGAGTGTGTC AGCATTGGGTTGGGCCCG 307
34/35 CCCTGTGACCTCCCACACCT GATCTGATGGAACTGAGCC 515
36 ACCACCTCGGTGCTTCTC TAGGACTAAATGGTCCTGCC 363
37 CCATGCACACATTTTCCAAC ATCCCACTAAACCCTTTCCAAc 325
38 GGACTAGGATCGGGGTCAG TGCTTCAGGGTTCTTTCTTG 306
39 TCATCCTCCTCCTCCAAGC GTATGGGCAGGGTCCGAAT 322
a All forward primers start 5′-TGTAAAACGACGGCCAGT.
b All reverse primers start 5′-CAGGAAACAGCTATGACC.
c Primers described by Hansen et al.12
Figure 2. Quantiﬁcation of normal and c.536delATGG mutant
transcripts in a heterozygous lymphoblastoid cell line. The relative
levels of normal (gray bar) and mutant mRNA transcripts were
quantiﬁed in a lymphoblastoid cell line derived from the proband’s
mother, who was heterozygous for the c.536delATGG mutation.
Error bars show the upper and lower limits of quantiﬁcation based
on three independent measurements. Cells were incubated in the
presence (diagonal stripes) or absence (black) of cycloheximide
(CHX) before RNA extraction.
The location of the SUR1missensemutations in patients
with PNDM is shown in ﬁg. 4. One example of each type
of genetic mutation (as shown in ﬁg. 1) was tested in an
in vitro functional assay using Xenopus oocytes (see ap-
pendix A). All mutations caused a signiﬁcant increase in
the ATP concentration required to half-maximally block
the channel (ﬁgs. 5 and 6). Importantly, the KATP current
at physiological ATP concentrations (3 mM MgATP) was
also signiﬁcantly increased (ﬁg. 5). This is expected to pro-
duce an increased KATP current in the beta cells of affected
patients and thus impair insulin secretion. We also ex-
amined the ATP sensitivity of the KATP channels expected
to occur in the unaffected parents. Compared with hom-
omeric A1185E or T229I/V1523L channels, the hetero-
zygous A1185E, T229I, and V1523L channels showed
greater ATP sensitivity and smaller KATP currents at 3 mM
MgATP (see ﬁg. 6). However, there was some overlap be-
tween the functional effects of the mutations present in
unaffected heterozygotes and those in patients with
PNDM (ﬁg. 5). Although none of the heterozygous mu-
tations had more-severe effects than their homozygous
counterpart, a clear distinction between the functional ef-
fects of the recessively acting heterozygous mutations and
the dominantly acting heterozygous or homozygous mu-
tations was not seen. This is in contrast to Kir6.2 muta-
tions, in which the phenotype, genotype, and functional
severity show a clear correlation.4 One explanation is that
the relative expression of wild-type andmutant SUR1 sub-
units differs between oocytes and human beta cells. An
alternative view is that there exists an unidentiﬁed cyto-
solic modulator, which interacts differentially with wild-
type and mutant SUR1, that is not present in our excised
patch studies.
Our results extend the spectrum of ABCC8 mutations
causing neonatal diabetes from activating mutations with
a dominant effect to include recessively acting gain-of-
function mutations that result in neonatal diabetes only
when homozygous, mosaic due to segmental uniparental
isodisomy, compound heterozygous for another activat-
ing mutation or if the second allele is inactivated. In con-
trast, all KCNJ11 mutations in patients with neonatal di-
abetes reported to date are heterozygous, dominant
mutations. Knowledge of the mode of inheritance is im-
portant when counseling the families of patients with
ABCC8 mutations about the risk of further family mem-
bers being affected. The risk that unaffected parents will
have a second affected child is considerably higher for
recessively acting mutations than for de novo dominant
Table 2. Details of ABCC8 Mutations and Clinical Information
ISPAD
Number Mutation (Protein Effect)
Nucleotide
Change Zygosity
Age at
Diagnosis
(wk)
Birth
Weighta
(Percentile)
Neurological Feature
Developmental
Delay
Muscle
Weakness Epilepsy
123 V86Ab c.257TrC Heterozygous 8 2,900 (9) No No No
124 V86G c.257TrG Heterozygous 5 2,900 (13) No No No
68 F132Lb c.394TrC Heterozygous 13 2,200 (!1) Yes Yes Yes
125 F132L c.394TrC Heterozygous 26 2,440 (9) Yes Yes No
82 F132V c.394TrG Heterozygous 20 NA No No No
46 D209E c.627CrA Heterozygous 5 2,720 (13) No No No
134 Q211Kb c.631CrA Heterozygous 16 2,400 (3) No No No
122 L225Pc c.674TrC Heterozygous 4 2,500 (11) No No No
117 E382K c.1144GrA Homozygous 8 2,700 (4) No No No
118 A1185E c.3554CrA Homozygous 0 4,200 (95) No Yes Yes
116 N72S c.215ArG Mosaic 5 3,870 (74) No No No
47 P45L  G1401R [c.134CrT]  [c.4201GrA] Compound heterozygous 6 2,520 (18) Yes Yes No
119 E208K  Y263D [c.622GrA]  [c.787TrG] Compound heterozygous 13 2,950 (28) Yes No No
120 T229I  V1523L [c.686CrT]  [c.4567GrT] Compound heterozygous 4 NA No No No
78 P207S  Y179X [c.619CrT]  [c.536_539delATGG] Compound heterozygous 8 3,290 (29) No No No
121 [E1327K; V1523A]  T1043QfsX74 [c.3979GrA; 4568CrT]  [c.3127_3129delACCinsCAGCCAGGACCTG] Compound heterozygous 1 2,380 (!1) No No No
a NA p not available. Birth weight is ﬁrst given in grams. Birth weight percentiles were calculated using population-based data,15 and, when information on gestational age was not available
( ), a gestational age of 40 wk was assumed.np 3
b Patients ISPAD 68, 123, and 134 have been reported by us elsewhere.9,10,14
c The L225P mutation has been reported in another patient by Masia et al.8
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Figure 3. Schematic representation of KATP channels in family
ISPAD 78. The unaffected parents are heterozygous for the
c.536del4 frameshift or P207S missense mutation. Lymphoblastoid
cells showed a decrease in c.536del4 mRNA (see ﬁg. 2), and the
majority of KATP channels in the proband are predicted to be hom-
omeric for the P207S mutation.
Figure 4. Schematic of the transmembrane topology of SUR1 showing the missense mutations identiﬁed. Recessive mutations are
shown in black and dominant mutations in green. NBD, nucleotide binding domain.
mutations (25% vs. the risk of germline mosaicism), but,
in the next generation, the offspring of the proband are
very unlikely to be affected for a recessively acting mu-
tation, compared with the 50% risk for a dominant het-
erozygous mutation.
Mutations in the ABCC8 gene encoding the SUR1 sub-
unit accounted for 27% of non-Kir6.2 PNDM in this co-
hort and are the most common cause after KCNJ11 mu-
tations. The phenotype was similar for dominantly acting
heterozygous ABCC8 mutations, recessive ABCC8 muta-
tions, and heterozygous KCNJ11 mutations,11 as shown by
age at diagnosis ( ) and birth weight, a biomarkerPp .14
for insulin secretion in utero ( ). Median birthPp .15
weight in this study was 2,710 g (percentile range !1–95),
with one macrosomic child reported (ISPAD 118). This
child received a diagnosis of diabetes in the 1st wk of life,
and his mother was not known to have diabetes during
the pregnancy; hence, his macrosomy remains unex-
plained. In contrast, for loss-of-functionABCC8mutations
causing hyperinsulinism, the common recessive muta-
tions result in a more severe hypoglycemia than the rare
dominant mutations that can often be treated with
diazoxide.16,17 The similarity of the phenotype in gain-of-
function beta cell KATP channelopathies implies that dia-
betes results from failure of channel closure in response
to ATP and that a further reduction in ATP sensitivity does
not lead to a more severe beta cell phenotype.
To our knowledge, this is the ﬁrst disease phenotype
reported to be a result of compound heterozygosity for
both gain-of-function and loss-of-function mutations. In
contrast, there are many examples of genes in addition to
ABCC8 in which mutations of opposite effects can result
in different phenotypes in different patients. For example,
activating GCK mutations cause hypoglycemia with in-
activating mutations resulting in hyperglycemia,18 gain-
of-function RET proto-oncogene mutations cause MEN2/
FMTC with loss-of-function mutations found in Hirsch-
sprung disease,19 and mutations in the SCNN1B and
SCNN1G genes encoding the epithelial sodium channel b
and g subunits can cause hypertension (Liddle syndrome;
dominant gain of function) or hypotension (pseudohy-
poaldosteronism type 1; recessive loss of function).20 We
propose that, in the patients we have described with
PNDM resulting from compoundheterozygous activating/
inactivating mutations, the loss-of-function mutation
leads to a decrease in functional protein, and the channels
are essentially homomeric for the activating SUR1 mu-
tation. This mutational mechanism is possible for other
channelopathies inwhich the functional channel is amul-
timeric structure.
Figure 5. A, Mean ( SEM) concentration of ATP required to half-maximally inhibit the KATP current (IC50) for the wild-type KATPchannel
(WT), channels carrying the indicated SUR1 mutations which cause neonatal diabetes (grey bars) and channels carrying the SUR1
mutations found in the unaffected parents (hatched bars). Numbers above the bars indicate the number of patches (oocytes) tested.
To simulate the patient’s genotype, we coinjected Kir6.2 mRNA with hetF132L (1:1 mix of WT and F132L SUR1 mRNAs); homA1185E or
P207S (mutant SUR1 only); or V1523LT229I (1:1 mix of V1523L and T229I SUR1). B, Mean (SEM) KATP current remaining in the
presence of 3mM MgATP in the inside-out patch for the wild-type KATP channel (WT; white bars) channels carrying the indicated SUR1
mutations which cause neonatal diabetes (grey bars) and channels carrying the SUR1 mutations found in the unaffected parents (hatched
bars). Numbers above the bars indicate the number of patches (oocytes) tested.
Figure 6. ATP sensitivity of KATP channels corresponding to those found in children with neonatal diabetes and their unaffected
parents. Mean relationship between [ATP] and the macroscopic KATP conductance (G), expressed relative to the conductance in the
absence of nucleotide (GC) for Kir6.2/SUR1 channels (WT, dashed lines), probands (dotted lines) or unaffected parents (solid lines). The
smooth curves are the best ﬁt of the Hill equation to the mean data. For wild-type channels, mM, , . ForIC p 15 hp 1.11 np 650
hetSUR1-F132L (a), mM, , and . For homSUR1-P207S (b), mM, , and . For SUR1-IC p 105 hp 0.72 np 5 IC p 65 hp 0.87 np 650 50
T229ISUR1V1523L (c), mM, , and . For homSUR1-A1185E (d), mM, , and . ForIC p 157 hp 0.91 np 8 IC p 35 hp 0.69 np 650 50
hetA1185E channels (d), mM, , and . For hetT229I channels (e), mM, , and . ForIC p 32 hp 1.0 np 5 IC p 17 hp 1.11 np 950 50
hetV1523L channels (f), mM, , and .IC p 45 hp 0.7 np 650
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Appendix A
Material and Methods
mRNA Analysis.—A custom real-time PCR assay for the
mutant and wild-type c.536delATGG sequences was ob-
tained from the Assays-by-Design service (Applied Biosys-
tems). Mutant and normal sequences were ampliﬁed with
a common primer set but differentiated by the binding of
real-time probes labeled with different ﬂuorochromes.
Probe and primer sequences were as follows: c.536 (for-
ward primer), 5′-GCTACGCTTCTGCCTCACA-3′; c.536
(reverse primer), 5′-CTCCTCACCCTGATGACATTGAC-3′;
c536WT (wild-type probe), 5′-CATCCCATAGAGGATC-3′;
and c.536delATGG (mutant probe), 5′-CAGCATCAGAGG-
ATC-3′. Probes were labelled 5′ with 6-FAM (6-ﬂuoroscein;
mutant) and VIC (normal) and 3′ with a minor groove-
binding protein (MGB) to enhance probing speciﬁcity. As-
says were designed to amplify both mRNA and genomic
sequences to allow the use of DNA for validationpurposes.
Probes and primers were validated using standard curve
analysis of triplicate serial 1:2 dilutions of heterozygous
cDNA to determine assay efﬁciency and linear range. Re-
actions contained 5 ml TaqMan Fast Universal Master Mix
no AmpErase (Applied Biosystems), and 0.5 ml Assays-by
Design probe and primermix (corresponding to 8 mMeach
primer and 36 mM each probe) in a total volume of 10 ml.
Ampliﬁcation conditions were a single cycle of 95C for
20 s followed by 40 cycles of 95C for 1 s and 60C for 20
s.
Total RNA was extracted from 2 # 106 lymphoblastoid
cells derived from the heterozygous father of the proband
for c.536delATGG and from two normal controls using
the Eppendorf Perfect RNA mini kit. Before reverse tran-
scription, normal and mutation-bearing mRNA samples
were pretreated with TURBO-DNAse (Ambion), according
to the manufacturers’ instructions, to remove contami-
nating genomic DNA. cDNA was reverse transcribed from
5 mg total RNA by use of the Thermoscript RT-PCR system
(Invitrogen).Mutant and normal sequences were then am-
pliﬁed from ectopic mRNA transcripts with a single-tube
TaqMan approach on the ABI Prism 7900 platform (Ap-
plied Biosystems). Triplicate single-round reactions were
performed for each cell line with use of 2 ml cDNA. Re-
action conditions are described above. Relative quantiﬁ-
cation of the two transcripts was performed with use of
the equation 2ddCt described by Applied Biosystems,which
refers to the efﬁciency of the PCR and the difference be-
tween the PCR crossing points (the point at which the
signal becomes visible over the background) for each allele
normalized to a DNA control (representing a 1:1 ratio of
mutant and wild-type targets). This is an accurate mea-
surement of relative abundance, which is independent of
ampliﬁcation and detection efﬁciency.
To establish whether differences in normal and mutant
transcripts were due to the action of the nonsense-me-
diated decay pathway on abnormal transcripts containing
premature-termination codons (PTCs), cultures were split
into two fractions and were treated with either the trans-
lation inhibitor cycloheximide (100 mg/ml) or the inert
carrier DMSO alone for a period of 4 h. After the incu-
bation, cells were washed once with PBS (Invitrogen),were
harvested, and were analyzed as described above.
Functional Studies.—HumanKir6.2 (GenBankNM_000525
with E23 and I337) and SUR1 (GenBank NM_000352 incor-
porating the alternate exon 17; also L78208 and L78224)
were used in this study. Both wild-type cDNAswere cloned
in the pBF vector. SUR1 mutants were then generated by
site-directed mutagenesis using the Quick-change XL sys-
tem (Stratagene). After plasmid linearization and puriﬁ-
cation, capped mRNA was prepared using the mMESSAGE
mMACHINE large-scale in vitro transcription kit (Ambion)
as described elsewhere.13
Currents were recorded from Xenopus laevis oocytes 1–
3 d after injection with 0.8 ng of wild-type Kir6.2 mRNA
and ∼4 ng of wild-type or mutant SUR1 mRNA (a 1:5
ratio). To simulate the heterozygous state (e.g., F132L),
Kir6.2 was coexpressed with a 1:1 mixture of wild-type
and mutant SUR1 mRNA. To simulate the compound
heterozygous state of hetSUR1-T229IhetSUR1-V1523L,
Kir6.2 was coexpressed with a 1:1 mixture of SUR1-T229I
and SUR1-V1523L mRNAs.
Macroscopic currents were recorded from giant inside-
out patches with use of the patch-clamp technique in re-
sponse to 3-s voltage ramps from 110 mV to 100 mV
(holding potential 0 mV) at 20C–22C. Currents were ﬁl-
tered at 0.15 kHz and digitized at 0.5 kHz. The pipette
solution contained (mM): 140 KCl, 1.2 MgCl2, 2.6 CaCl2,
10 HEPES (pH 7.4 with KOH). The internal (bath) solution
contained (mM): 107 KCl, 2 MgCl2, 1 CaCl2, 10 EGTA, 10
HEPES (pH 7.2 with KOH) and Mg nucleotides (as indi-
cated). The macroscopic slope conductance was measured
between 100mV and 10mV. ATP concentration-re-
sponse curves in the absence of Mg2 were ﬁtted with the
Hill equation. To control for possible rundown of channel
activity, was taken as the mean of the conductance inGc
control solution before and after ATP application. Con-
centration-response curves were ﬁtted individually for
each patch, and the mean  SEM of the individual pa-
rameters are given in the text.
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Web Resources
Accession numbers and URLs for data presented herein are as
follows:
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for ABCC8
[accession number NM_000352.2 incorporating the alternate
exon 17: L78208, L78224], Kir6.2 [accession number NM_
000525 with E23 and I337], and SUR1 [accession number
NM_000352 incorporating the alternate exon 17; also L78208
and L78224])
International Society for Pediatric and Adolescent Diabetes, http:
//www.ispad.org/
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for KCNJ11, ABCC8, congenital hyper-
insulinism, and PNDM)
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